Janssen/Legend’s Cilta-Cel Consistent In Earlier Myeloma, Longer-Term Results
Bristol’s Abecma Beat CAR-T To Market, Maybe Not In Second-Line
The partners reported initial data at ASH for their BCMA-targeting CAR-T therapy in second-line multiple myeloma that appear consistent with longer-term results and ahead of their main competitor, Bristol’s Abecma.
